FOS and breast cancer: Nicely fitting with these data, in silico analyses revealed that the expression of c-Fos, EGR1 and CYR61 is significantly higher in ER-positive BC patients displaying EGFR and GPER levels above the median value, compared to patients exhibiting the expression of both receptors below the median value (Fig. 3E-G).